Cargando…
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
We have reported that IgG antibody responses following two mRNA COVID-19 vaccinations are impaired among patients with multiple myeloma (MM). In the current study, sixty-seven patients with MM were tested for anti-spike IgG antibodies 0–60 days prior to their first vaccination, 14–28 days following...
Autores principales: | Goldwater, Marissa-Skye, Stampfer, Samuel D., Sean Regidor, Bernard, Bujarski, Sean, Jew, Scott, Chen, Haiming, Xu, Ning, Kim, Clara, Kim, Susanna, Berenson, James R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of British Infection Association.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744558/ https://www.ncbi.nlm.nih.gov/pubmed/36530752 http://dx.doi.org/10.1016/j.clinpr.2022.100214 |
Ejemplares similares
-
Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma
por: Stampfer, Samuel D., et al.
Publicado: (2023) -
Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients
por: Stampfer, Samuel D., et al.
Publicado: (2021) -
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
por: Stampfer, Samuel D., et al.
Publicado: (2021) -
Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination
por: Stampfer, Samuel D., et al.
Publicado: (2022) -
Oral step-down for Staphylococcus aureus bacteraemia: An opportunity for antimicrobial stewardship?
por: Platts, Stephen, et al.
Publicado: (2022)